Investor Presentaiton
Company overview
Financial review
2022 priorities
Appendix
References
2022 full year guidance
Expected, barring unforeseen events; growth vs. PY in cc
Innovative
Medicines
Sales to grow mid single digit
Core Oplnc to grow mid to high single digit, ahead of sales
Sales to grow low single digit (revised upwards from broadly in line)
Sandoz
Core Oplnc to be broadly in line with prior year (revised upwards from to decline low to mid single digit)
Sales to grow mid single digit
Group
Core Oplnc to grow mid single digit
Key assumptions
Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics, and that no
GilenyaⓇ and no SandostatinⓇ LAR generics enter in the US.
In June 2022, an appeals court held the Gilenya US dosing regimen patent invalid. Novartis plans to petition the appeals court for further review
to uphold validity of the dosing regimen patent. There is no generic competition in the US at this time. In Q2, Gilenya US sales were USD 332m,
US sales have been steadily declining due to competitive pressures.
23 Investor Relations | Q2 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation